| Literature DB >> 35096609 |
Haolin Yin1, Yu Jiang2, Zihan Xu3, Wenjun Huang1, Tianwu Chen4, Guangwu Lin1.
Abstract
BACKGROUND ANDEntities:
Keywords: breast cancer; deep learning; diffusion-weighted imaging; ductal carcinoma in situ; magnetic resonance imaging
Year: 2022 PMID: 35096609 PMCID: PMC8795910 DOI: 10.3389/fonc.2021.805911
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Flowchart of inclusion and exclusion.
Scanning parameters of diffusion-weighted imaging protocols on 3.0 Tesla scanners.
| Trio | Verio | Prisma | |
|---|---|---|---|
| Orientation | Axial | Axial | Axial |
| Repetition time (msec) | 5000 | 4300 | 6400 |
| Echo time (msec) | 66 | 80 | 60 |
| Field of view (cm) | 34 × 34 | 34 × 34 | 34 × 34 |
| Matrix size | 256 × 256 | 256 × 256 | 256 × 256 |
| Echo train length | 1 | 1 | 1 |
| Slice thickness (mm) | 4.0 | 5.0 | 4.0 |
| b value (s/mm2) | 0, 1000 | 0, 1000 | 0, 1000 |
| Gap (mm) | 1.0 | 1.0 | 1.5 |
Figure 2Delineation and preprocessing of regions of interest on apparent diffusion coefficient images.
Figure 3Architecture of the convolutional neural network.
Clinicopathological characteristics of the participants.
| Characteristic | Tra and Val Sets | Internal Test Set | External Test Set |
|
|---|---|---|---|---|
| Patients | 560 | 140 | 102 | |
| Age | 48.5 (29–84) | 50.4 (31–79) | 50.7 (35–74) | 0.321 |
| <40 y | 118 (21.1) | 26 (18.6) | 13 (12.7) | |
| 40-49 y | 193 (34.5) | 47 (33.6) | 38 (37.3) | |
| 50-59 y | 142 (25.3) | 44 (31.4) | 34 (33.3) | |
| ≥60 | 107 (19.1) | 23 (16.4) | 17 (16.7) | |
| Menopausal status | 0.572 | |||
| Premenopausal | 293 (52.3) | 67 (47.9) | 55 (53.9) | |
| Postmenopausal | 267 (47.7) | 73 (52.1) | 47 (46.1) | |
| Tumor size | 0.848 | |||
| ≤2.0 cm | 258 (46.1) | 61 (43.6) | 41 (40.2) | |
| 2.1-4.0 cm | 253 (45.2) | 67 (47.9) | 51 (50.0) | |
| >4.0 cm | 49 (8.7) | 12 (8.5) | 10 (9.8) | |
| Lesion position | 0.053 | |||
| Right | 296 (52.8) | 75 (53.5) | 41 (39.9) | |
| Left | 264 (47.2) | 65 (46.5) | 61 (60.1) | |
| Morphology | 0.683 | |||
| Mass | 484 (86.5) | 119 (85.3) | 85 (83.1) | |
| Non-mass | 76 (13.5) | 21 (14.7) | 17 (16.9) | |
| Histologic type | 0.619 | |||
| Invasive | 316 (56.4) | 84 (60.0) | 55 (53.9) | |
| DCIS | 244 (43.6) | 56 (40.0) | 47 (46.1) | |
| Tumor grade | 0.063 | |||
| Low | 87 (15.5) | 28 (19.9) | 23 (23.1) | |
| Moderate | 298 (53.3) | 81 (57.8) | 45 (43.8) | |
| High | 175 (31.2) | 31 (22.3) | 34 (33.1) |
Tra and val sets, Training and validation sets; DCIS, ductal carcinoma in situ.
Performance of the CNN model and mean ADC.
| Internal Test Set (140) | External Test Set (102) | Tra and Val Sets (560) | |||
|---|---|---|---|---|---|
| CNN Model | Mean ADC | CNN Model | Mean ADC | Mean ADC | |
| Accuracy | 0.907 | 0.836 | 0.902 | 0.824 | 0.845 |
| Sensitivity | 0.893 | 0.845 | 0.873 | 0.818 | 0.864 |
| Specificity | 0.929 | 0.821 | 0.894 | 0.829 | 0.820 |
| PPV | 0.949 | 0.877 | 0.906 | 0.849 | 0.861 |
| NPV | 0.852 | 0.780 | 0.857 | 0.796 | 0.823 |
| F1 score | 0.908 | 0.836 | 0.882 | 0.824 | 0.845 |
| kappa value | 0.809 | 0.661 | 0.764 | 0.646 | 0.684 |
| AUC (95% CI) | 0.977 (0.957-0.998) | 0.866 (0.805-0.927) | 0.926 (0.876-0.976) | 0.845 (0.766-0.925) | 0.868 (0.838-0.899) |
AUC, area under the receiver operating characteristic curve; CI, confidence interval; CNN, convolutional neural network; NPV, negative predictive value; PPV, positive predictive value; Tra and val sets, training and validation sets; ADC, apparent diffusion coefficient.
Figure 4Mean ADC of the invasive breast cancer group and breast ductal carcinoma in situ group in the internal test set (A) external test set (B) and training and validation sets (C). Relationship between the Youden index and threshold in the internal test set (D) external test set (E) and training and validation sets (F).
Figure 5Receiver operating characteristic curve analysis for the differentiation of breast ductal carcinoma in situ and invasive breast cancers in the internal test set (A) and the external test set (B).
Figure 6Loss curves (A) and accuracy curves (B) of the training and validation sets.